Abstract
A new, single-application formulation containing terbinafine has recently been approved for the treatment of athlete’s foot. An expert panel of dermatologists was convened to provide guidance on the important attributes of this new film-forming solution (FFS), how best to inform potential users on these benefits and how to ensure appropriate use. A consumer survey about tinea pedis revealed an average disease duration of 7 years, an average of four recurrences per year, patient concerns about itching and foot odor, but a poor level of patient knowledge on the cause of tinea pedis and available treatments. A review of the clinical trial data that led to the successful registration of the FFS demonstrated that treatment was both effective and well tolerated. The panel also considered data supporting the treatment of the entire lateral and undersurface areas of both feet, rather than lesions that are just symptomatic, usually the interdigital spaces, as previously recommended, and discussed guidelines for use of the new formulation. Discussion focused on the value of single-dose treatment in addressing noncompliance with treatment for the correct duration, guidelines for treatment of both feet and the need for an educational program on the FFS for dermatologists and pharmacists, and appropriate instructions for patients. The panel concluded that new single-dose therapy with terbinafine FFS presents a novel treatment opportunity owing to its simplicity of application. This provides an opportunity to develop new ways of increasing interaction between dermatologists, pharmacists, scientific/news media and patients, so that there is full understanding of the value of the new treatment.
